Overview

A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234

Status:
Completed
Trial end date:
2019-12-04
Target enrollment:
Participant gender:
Summary
The objective of this two part study was to demonstrate safety, tolerability, and pharmacokinetics of RT234 in healthy volunteers. This study is also known as Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 1 (VIPAH-PRN 1) study
Phase:
Phase 1
Details
Lead Sponsor:
Respira Therapeutics, Inc.
Treatments:
Vardenafil Dihydrochloride